[1]许溪麟 李小明.艾多沙班在心血管疾病应用的研究进展[J].心血管病学进展,2024,(5):451.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.016]
　XU Xilin,LI Xiaoming.Application of Edoxaban in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(5):451.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.016]
点击复制

艾多沙班在心血管疾病应用的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年5期
页码:
451
栏目:
综述
出版日期:
2024-05-25

文章信息/Info

Title:
Application of Edoxaban in Cardiovascular Disease
作者:
许溪麟1 李小明2
(1.山西医科大学山西 太原 030000；2.山西省心血管病医院心血管内科,山西 太原 030000)
Author(s):
XU Xilin1; LI Xiaoming2
?1.Second Hospital of Shanxi Medical UniversityTaiyuan 030000,Shanxi,China; 2.Department of Cardiology,Shanxi Cardiovascular HospitalTaiyuan 030000,Shanxi,China)
关键词:
艾多沙班; 非瓣膜性心房颤动; 非维生素K拮抗剂口服抗凝药物; 心血管疾病
Keywords:
Edoxaban; Non-valvular atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Cardiovascular disease
DOI:
10.16806/j.cnki.issn.1004-3934.2024.05.016
摘要:
新型口服抗凝药物艾多沙班作为直接Xa因子抑制剂，具有口服吸收快、药物和食物相互作用小、无需常规监测凝血指标且具有良好的耐受性、安全性及依从性等优势。尽管上市时间较晚，但其在心血管疾病的临床应用越来越广泛，现将艾多沙班在心血管疾病中的研究进展做一综述。
Abstract:
Edoxaban,a new oral anticoagulant,as a direct factor Xa inhibitor,has the advantages of rapid oral absorption,small interaction between drug and food,no routine monitoring of coagulation indicators,good tolerance,safety and compliance. Although it has been on the market late,it is more and more widely used in the clinical practice of cardiovascular disease. This article reviews the research progress of edoxaban in cardiovascular disease

参考文献/References:

[1] Zhang C,Gu ZC,Ma EL,et al. Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China[J]. Eur J Clin Pharmacol,2023,79(12):1631-1639.
[2] Corsini A,Ferri N,Proietti M,et al.Edoxaban and the issue of drug-drug interactions:from pharmacology to clinical practice[J]. Drugs,2020,80(11):1065-1083.
[3] Srinivasan S,Ajmal M,Pecci C,et al. Edoxaban in cardiovascular disease management:review[J]. Br J Clin Pharmacol,2022,88(2):535-540.
[4] Goette A,Mollenhauer M,Rudolph V,et al. Pleiotropic effects of NOACs with focus on edoxaban:scientific findings and potential clinical implications[J]. Herzschrittmacherther Elektrophysiol,2023,34(2):142-152.
[5] de Groot JR,Weiss TW,Kelly P,et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care:1-year follow-up of the prospective observational ETNA-AF-Europe study[J]. Eur Heart J Cardiovasc Pharmacother,2021,7(FI1):f30-f39.
[6] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会,中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动:目前的认识和治疗建议(2021)[J]. 中华心律失常学杂志,2022,26(1):15-88.
[7] Steffel J,Collins R,Antz M,et al. 2021 European Heart Rhythm Association ractical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace,2021,23(10):1612-1676.
[8] 中华医学会心血管病学分会,中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志,2023,51(6):572-618.
[9] Marston XL,Wang R,Yeh YC,et al. Comparison of clinical outcomes of edoxaban versus apixaban,dabigatran, rivaroxaban,and vitamin K antagonists in patients with atrial fibrillation in Germany:a real-world cohort study[J]. Int J Cardiol,2022,346:93-99.
[10] Patti G,Wang R,Marston XL,et al. Anticoagulant treatment adherence and persistence in German patients with atrial fibrillation[J]. Cardiol Ther,2023,12(2):371-391.
[11] Liu X,Huang M,Ye C,et al. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation:a PRISMA-compliant article[J]. Medicine(Baltimore),2020,99(27):e21025.
[12] Xu W,Lv M,Wu S,et al. Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation:a systematic review and network meta-analysis[J]. Cardiovasc Drugs Ther,2023,37(2):363-377.
[13] Yamashita T,Koretsune Y,Yang Y,et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation—An ENGAGE AF-TIMI 48 subanalysis[J]. Circ J,2016,80(4):860-869.
[14] Akashi S,Oguri M,Ikeno E,et al. Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial[J]. JAMA Netw Open,2022,5(8):e2228500.
[15] Yoshida T,Nakamura A,Funada J,et al. Efficacy and safety of edoxaban 15 mg according to renal function in very elderly patients with atrial dibrillation:a subanalysis of the ELDERCARE-AF trial[J]. Circulation,2022,145(9):718-720.
[16] de Caterina R,Kim YH,Koretsune Y,et al. Safety and effectiveness of edoxaban in atrial fibrillation patients in routine clinical practice:one-year follow-up from the global noninterventional ETNA-AF program[J]. J Clin Med,2021,10(4):573.
[17] Kirchhof P,Bakhai A,de Groot JR,et al. Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation:4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study[J]. Eur Heart J,2023,44(suppl 2):ehad655.552.
[18] Diemberger I,Chen C,Choi J,et al. Persistence to edoxaban treatment in patients with atrial fibrillation:analysis from the Global ETNA-AF program[J]. Eur Heart J,2023,44(suppl 2):ehad655.334.
[19] Fukamachi D,Okumura Y,Matsumoto N,et al. Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease[J]. J Interv Cardiol,2022,2022:5905022.
[20] Vranckx P,Valgimigli M,Eckardt L,et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI):a randomised,open-label,phase 3b trial[J]. Lancet,2019,394(10206):1335-1343.
[21] Vranckx P,Valgimigli M,Eckardt L,et al. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation:a pre-specified analysis of the ENTRUST-AF PCI trial[J]. Eur Heart J,2020,41(47):4497-4504.
[22] Hohnloser SH,Camm J,Cappato R,et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation:the ELIMINATE-AF trial[J]. Eur Heart J,2019,40(36):3013-3021.
[23] Takahashi N,Mukai Y,Kimura T,et al. Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation—The prospective KYU-RABLE study[J]. Circ J,2019,83 (10):2017-2024.
[24] Park DW,Ahn JM,Kang DY,et al. Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR:the ADAPT-TAVR randomized clinical trial[J]. Circulation,2022,146(6):466-479.
[25] Kim M,Ahn JM,Kang DY,et al. Low-or standard-dose edoxaban versus antiplatelet therapy for leaflet thrombus and cerebral thromboembolism after TAVR:a pre-specified analysis of randomized ADAPT-TAVR trial[J]. Am Heart J,2024,269:167-178.
[26] van Mieghem NM,Unverdorben M,Hengstenberg C,et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR[J]. N Engl J Med,2021,385(23):2150-2160.
[27] Kirchhof P,Toennis T,Goette A,et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes[J]. N Engl J Med,2023,389(13):1167-1179.
[28] Becher N,Toennis T,Bertaglia E,et al. Anticoagulation with edoxaban in patients with long atrial high-rate episodes≥24?hours[J]. Eur Heart J,2024,45(10):837-849.?
[29] Stevens SM,Woller SC,Kreuziger LB,et al. Antithrombotic therapy for VTE disease:second update of the CHEST guideline and expert panel report[J]. Chest,2021,160(6):e545-e608.
[30] Nakamura M,Yamada N,Asamura T,et al. Safety and effectiveness of edoxaban in Japanese venous thromboembolism patients—Final analysis of one-year follow-up data from a Japanese postmarketing observational study(ETNA-VTE-Japan)[J]. Circ Rep,2020,2(3):192-202.
[31] Yamashita Y,Fukasawa T,Takeda C,et al. Clinical characteristics and outcomes of patients with venous thromboembolism receiving edoxaban in the real world[J]. Circ J,2024,88(3):371-379.
[32] Li JL,Zhang M,Mai JL,et al. Short-term efficacy and safety of edoxaban for venous thromboembolism after total hip or knee arthroplasty:a systematic review and meta-analysis[J]. Eur Rev Med Pharmacol Sci,2022,26(15):5540-5552.
[33] Konstantinides SV,Meyer G,Becattini C,et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society(ERS):The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology(ESC)[J]. Eur Respir J,2019,54(3):1901647.
[34] Raskob GE,van Es N,Verhamme P,et al. Edoxaban for the treatment of cancer-associated venous thromboembolism[J]. N Engl J Med,2018,378(7):615-624.
[35] Grifoni E,Baroncelli A,Pinto G,et al. Efficacy and safety of edoxaban in cancer-associated venous thromboembolism:a real world retrospective study[J].TH Open,2022,6(2):e99-e106.?
[36] Yamashita Y,Morimoto T,Muraoka N,et al. Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis(ONCO DVT study):an open-label,multicenter,randomized clinical trial[J]. Circulation,2023,148(21):1665-1676.
[37] Kakkos SK,Gohel M,Baekgaard N,et al. Editor’s Choice—European Society for Vascular Surgery(ESVS) 2021 clinical practice guidelines on the management of venous thrombosis[J]. Eur J Vasc Endovasc Surg,2021,61(1):9-82.
[38] Toyoda K,Arakawa S,Ezura M,et al. Andexanet alfa for the reversal of factor Xa inhibitor activity:prespecified subgroup analysis of the ANNEXA-4 study in Japan[J]. J Atheroscler Thromb,2024,31(3):201-213.
[39] Gomez-Outes A,Alcubilla P,Calvo-Rojas G,et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants[J]. J Am Coll Cardiol,2021,77(24):2987-3001.
[40] Meijers J,Bakhtiari K,Zwiers A,et al. OKL-1111,a modified cyclodextrin as a potential universal reversal agent for anticoagulants[J]. Thromb Res,2023,227:17-24.

相似文献/References:

[1]彭金华,王平,胡婧,等.左心耳封堵术对非瓣膜性心房颤动患者心脏利尿钠肽分泌功能的影响[J].心血管病学进展,2019,(6):873.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.009]
　PENG Jinhua,WANG PingHU Jing,YANG Jingqi,et al.Effect of Left Atrial Appendage Closure on Cardiac Natriuretic Peptide Secretion in Patients with Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(5):873.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.009]
[2]金铁托 阮中宝.左心耳封堵术对患者系统内稳态的影响[J].心血管病学进展,2020,(12):1268.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.011]
　JIN Tietuo,RUAN Zhongbao.Effect of Left Atrial Appendage Closure on Systemic Homeostasis in Patients[J].Advances in Cardiovascular Diseases,2020,(5):1268.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.011]
[3]邓蕊 李洪仕 蔡衡.左心耳封堵术对非瓣膜性心房颤动合并冠状动脉性心脏病的价值[J].心血管病学进展,2022,(11):966.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.002]
　DENG Rui,LI Hongshi,CAI Heng.Value of Left Atrial Appendage Closure on Non-Valvular Atrial Fibrillation with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2022,(5):966.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.002]
[4]秦可隽?姜述斌.左心耳封堵术对非瓣膜性心房颤动患者左心功能影响的研究进展[J].心血管病学进展,2024,(5):425.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.010]
　QIN KejuanJIANG Shubin.Effects of Left Atrial Appendage Closure on Left Heart Function in Patients with Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(5):425.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.010]

更新日期/Last Update: 2024-06-28